EP Patent

EP4519270A1 — Process for preparing relugolix and intermediates thereof

Assigned to Scinopharm Taiwan Ltd · Expires 2025-03-12 · 1y expired

What this patent protects

The present disclosure provides improved processes for the preparation of Relugolix and intermediates thereof. Relugolix is prepared via intermediates (M7) and (M8):, wherein X is as described herein. Present disclosure also provides three additional routes to prepare Relugolix a…

USPTO Abstract

The present disclosure provides improved processes for the preparation of Relugolix and intermediates thereof. Relugolix is prepared via intermediates (M7) and (M8):, wherein X is as described herein. Present disclosure also provides three additional routes to prepare Relugolix and intermediates thereof, where the starting material of ethyl 2- amino-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate (SM1) is protected by coupling with an acyl chloride, a hydroxylamine or an oxime.

Drugs covered by this patent

Patent Metadata

Patent number
EP4519270A1
Jurisdiction
EP
Classification
—
Expires
2025-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Scinopharm Taiwan Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.